Stockreport

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Rallybio Corporation  (RLYB) 
PDF – Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 –   – Data Readouts for Completed Study Expected in 4Q 2025 – [Read more]